Printer Friendly
The Free Library
14,506,614 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Elan Announces Manufacturing Agreement with Lilly.


Business Editors/Health/Medical Writers

DUBLIN, Ireland--(BUSINESS WIRE)--June 10, 2004

Elan Corporation, plc announced today that it has entered into a manufacturing and supply agreement with Eli Lilly and Company Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company and one of the world's largest corporations. Eli Lilly's global headquarters is located in Indianapolis, Indiana, in the United States.  (Lilly) under which Elan will supplement Lilly's manufacture of duloxetine hydrochloride duloxetine hydrochloride

Cymbalta

Pharmacologic class: Selective serotonin and norepinephrine reuptake inhibitor

Therapeutic class: Antidepressant

Pregnancy risk category C

 capsules beginning in mid-2005.

Kelly Martin, Elan's President and Chief Executive Officer, said, "This agreement represents a significant milestone for Elan as it is our first large-scale manufacturing agreement with a leading pharmaceutical company. It represents a further specific example of our commitment to remain focused on execution and deliver results and value to the marketplace."

The capsule form of duloxetine will be manufactured in Elan's Athlone, Ireland facility, a fully compliant U.S. Food & Drug Administration/European Medicines Agency approved site. In 2003, Elan completed a US $178 million expansion of the Athlone site. The campus now houses a 138,000 square foot, current Good Manufacturing Practices Good Manufacturing Practice or GMP (also referred to as 'cGMP' or 'current Good Manufacturing Practice') is a term that is recognized worldwide for the control and management of manufacturing and quality control testing of foods and pharmaceutical products.  (cGMP) manufacturing facility. Financial terms of the agreement were not disclosed.

About Elan

Elan Corporation, plc is a neuroscience-based biotechnology company that is focused on discovering, developing, manufacturing and marketing advanced therapies in neurology, autoimmune diseases Autoimmune diseases
A group of diseases, like rheumatoid arthritis and systemic lupus erythematosus, in which immune cells turn on the body, attacking various tissues and organs.

Mentioned in: Complement Deficiencies, Premature Menopause
, and severe pain. Elan (NYSE NYSE

See: New York Stock Exchange
: ELN Noun 1. ELN - a Marxist terrorist group formed in 1963 by Colombian intellectuals who were inspired by the Cuban Revolution; responsible for a campaign of mass kidnappings and resistance to the government's efforts to stop the drug trade; "ELN kidnappers target ) shares trade on the New York New York, state, United States
New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of
, London and Dublin Stock Exchanges.

This news release contains forward-looking statements that involve risks and uncertainties and reflects Elan's judgment as of the date of this release. Actual events or results may differ from Elan's expectations. For example, we may not be able to manufacture the duloxetine hydrochloride capsules by mid-2005. A further list of risks, uncertainties and other matters can be found in Elan's Annual Report on Form 20-F for the fiscal year ended December 31, 2003 and in its Reports of Foreign Issuer on Form 6-K. Elan assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
COPYRIGHT 2004 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:4EUIR
Date:Jun 10, 2004
Words:307
Previous Article:Independent Bank Corp. Announces Quarterly Dividend.
Next Article:S&P Announces: Triad Guaranty Insurance Corp. and Parent Ratings Affirmed; Outlook Stable.
Topics:



Related Articles
MARKET REACTION NOT POSITIVE TO MINIMED DISTRIBUTION DEALS.(Business)
Ligand Restructures AVINZA License and Supply Agreement.
Ligand Completes Restructuring of AVINZA License and Supply Agreement; New Agreement Improves AVINZA Profit Margin, Facilitates Co-Promotion...
Elan Announces Continued Progress.
Elan Announces Agreement with Vernalis Regarding North American Rights for Frova.
Elan Announces Strategic Transaction; Eisai to Purchase Elan's Interests in Zonegran in North America and Europe.
Elan Licenses Its NanoCrystal Technology to Roche.
Elan Completes Sale of Zonegran to Eisai.
Elan Completes Sale of Frova to Vernalis.
Elan Reports Second Quarter 2004 Financial Results.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles